From accelerating clinical trials and gaining regulatory approval to expanding access and understanding market needs, this webinar will cover the basics of what makes real-world data regulatory and research grade and how it can transform your R&D programs for rheumatology, immunology, and other chronic conditions, including RA, SLE, and MS.
Join Dr. Richard Gliklich, CEO of OM1, as he explores:
Dr. Richard Gliklich is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.
Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.
Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.
Arsalan Arif is a news media entrepreneur who set out in 2015 to build his vision of an independent biotech news company at Endpoints News.